Redeye gives its initial take on BONESUPPORT’s Q2 report. Sales and EBIT were slightly below consensus, but what is most noticeable is the US sales development during Q2, where sales were practically flat between Q1 and Q2. On constant exchange rates, things look better in these volatile times, but we still suspect a slight negative share price reaction during the day.
LÄS MER
